BioNTech SE Receivables

BioNTech SE (BNTX) currently reports a receivables of $610M as of March 2026. That compares with $1B in the prior-year period — down 40.3% year over year. Use the charts on this page to explore BioNTech SE's receivables history and peer comparisons.

BioNTech SE's receivables decreased from $1B to $610M — a 40.3% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BioNTech SE reported $610M in receivables as of March 2026. That compares with $1B in the prior-year period — down 40.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $610M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for BioNTech SE, and consider following BNTX for alerts when major investors trade the stock.

BioNTech SE is classified in the Healthcare sector. On receivables, it currently shows $610M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BNTX with unrelated industries.